Fibrates and their receptor, namely peroxisome proliferator-activated receptor a (PPARa), have been reported to regulate bile acid (BA) synthesis and transport. However, the effect of fibrate treatment and PPARa activation on BA homeostasis remains controversial. In this study, both wild-type (WT) and PPARa-null male mice were treated with clofibrate (CLOF) for 4 days to evaluate the effects of short-term PPARa activation on BA homeostasis. Although a decrease in total BAs (RBAs) was observed in livers of CLOF-treated WT mice, it was not observed in PPARa-null mice. CLOF-mediated decrease in RBAs in the liver was not likely due to the reduction in BA synthesis or BA uptake, as evidenced by an increase in the BA synthetic enzyme (Cyp7a1) and 2 BA uptake transporters (Na (þ)-taurocholate cotransporting polypeptide [Ntcp] and organic anion transporting polypeptide [Oatp]1b2). Instead, the decrease in liver BAs by CLOF is largely a result of increased biliary excretion of BAs, which was associated with a significant induction of the canalicular efflux transporter (bile salt export pump [Bsep]) in the liver. The PPARa-mediated increase in Cyp7a1 in CLOF-treated WT mice was not due to farnesoid X receptor (Fxr)-small heterodimer partner (Shp) signaling in the liver, but due to suppression of Fxr-fibroblast growth factor15 signaling in the ileum. Additionally, CLOF also suppressed intestinal BA transporters (apical sodium-dependent bile acid transporter and organic solute transporterb) and cholesterol efflux transporters (Abcg5 and Abcg8) in a PPARadependent manner. In summary, this study provides the first comprehensive analysis on the effect of a short-term CLOF treatment on BA homeostasis, and revealed an essential role of PPARa in regulating BA synthesis, transport and signaling.
For decades fibrates have been widely used as hypolipidemic drugs to efficiently reduce plasma triglyceride levels (Schoonjans et al., 1996) . The finding that fibrates lower serum alkaline phosphate (ALP) initiated numerous clinical studies to explore the efficacy of fibrates to treat cholestasis, a condition characterized with impaired bile flow in patients with primary biliary cirrhosis and primary sclerosing cholangitis (Day et al., 1993; Honda et al., 2013) . These therapeutic effects of fibrates are mainly the result of activation of the peroxisome proliferatoractivated receptor alpha (PPARa), a nuclear receptor most highly expressed in liver, which regulates hepatic pathways for energy homeostasis, hepatic detoxification, inflammatory response, and hepatocellular carcinogenesis (Rakhshandehroo et al., 2010) .
The synthesis of bile acids (BAs) from cholesterol is the predominant mechanism to eliminate cholesterol from the body. The detergent properties make BAs not only an effective emulsifier to promote intestinal nutrient absorption and solubilize biliary cholesterol, but also are cytotoxic chemicals at high concentrations (Hofmann, 2009a) . Individual BAs have distinct structures dependent on the number and position of hydroxyl groups, as well as conjugation with taurine and glycine. The structural diversity of BAs confers different hydrophobicity and thus various capabilities to solubilize cholesterol and to cause hepatotoxicity (Heuman, 1989) . For this reason, the synthesis, transport, and metabolism of BAs are tightly regulated to achieve their normal physiological functions (Hofmann, 2009a,b) .
Although the hypocholesterolemic effect of fibrates has been partially attributed to their effect on BA metabolism, controversial results have been reported on the in vitro and in vivo role of fibrates and PPARa in regulating BA synthesis. In liver, BAs are synthesized predominantly in the classic pathway, and to a less extent the alternative pathway. Cyp7a1 is the rate-limiting enzyme in the classic pathway of BA synthesis, and Cyp8b1 determines the ratio of cholic acid (CA) to chenodeoxycholic acid (CDCA). Both fatty acids (endogenous PPARa ligands) and Wy14643 (a potent PPARa agonist) activate murine and human CYP7A1 promoters through PPARa in transfected rat hepatoma cells (Cheema and Agellon, 2000) . This is contradictory to 2 previous studies that PPARa and Wy14643 repress both human and rat CYP7A1 promoters in a human liver cell line (Marrapodi and Chiang, 2000; Patel et al., 2000) . Cyp8b1 mRNA was increased by both 1 week of Wy14643 (2-fold increase) and 24-h fasting (>4-fold increase), which is PPARa-dependent (Hunt et al., 2000) . Cyp7a1 mRNA was not altered by one week of Wy14643, but increased about 2-fold by 24-h fasting in a PPARa-dependent manner. In contrast, both 17 days of ciprofibrate and 12 months of bezafibrate in mice were shown to reduce Cyp7a1 about 78% and 92%, respectively (Hays et al., 2005; Post et al., 2001) . These studies demonstrate a contradictory role of PPARa in regulating BA synthesis, with PPARa being involved in ciprofibrate-mediated Cyp7a1 suppression, but not in bezafibrate-mediated effects. Thus, significant gaps remain in our understanding of the effect of fibrate treatments and PPARa activation on BA homeostasis.
Despite a variety of studies addressing the effects of fibrates on BAs, comprehensive analysis of PPARa-mediated effects on BA profile, synthesis, transport and signaling is surprisingly limited. Previous studies frequently involved long term feeding of fibrates to investigate the effects of PPARa activation on BA synthesis. In such circumstances, the exact role of PPARa is easily obscured by secondary and indirect effects following fibrate treatment. For this reason, this study aimed to systematically investigate the effects of short-term PPARa activation on BA homeostasis. Clofibrate (CLOF) was chosen for this study due to its 10-fold higher selectivity for PPARa over other PPAR isoforms, as well as its wide use as an experimental PPARa agonist in rodents (Dreyer et al., 1993) . Both wild-type (WT) and PPARa-null male mice were treated with CLOF for 4 days, and the PPARa-dependent effects of CLOF on liver and bile BA profiles, as well as the major pathways of BA regulation, synthesis, and transport were investigated.
MATERIALS AND METHODS
Chemicals and reagents. BA standards used in this study were purchased from either Steraloids, Inc. (Newport, Rhode Island) or Sigma-Aldrich (St Louis, Missouri). Clofibric acid (CLOF) was purchased from Sigma-Aldrich Co. Chloroform, agarose, and ethidium bromide were purchased from AMRESCO Inc. (Solon, Ohio). RNA-Bee was purchased from TelTest Inc. (Friendswood, Texas) . All other chemicals, unless indicated, were purchased from Sigma-Aldrich Co.
Animals and treatment. Adult male C57BL/6 mice were purchased from Charles River Laboratories Inc.
(Wilmington, Massachusetts). PPARa-null mice were provided by the laboratory of Dr Frank J. Gonzalez (Lee et al., 1995) . All animal studies were approved by the Institutional Animal Care and Use Committee at the University of Kansas Medical Center. All mice were housed in an Association for Assessment and Accreditation of Laboratory Animal Care-accredited facility with a 12:12-h light:dark cycle and provided chow (Teklad Rodent Diet No. 8604, Harlan Teklad, Madison, WI) and water ad libitum. In this study, corn oil (CO) or CLOF (300 mg/kg in CO) in a volume of 5 ml/kg was administered (i.p.) daily for 4 consecutive days to male WT and PPARa-null mice. This CLOF treatment regimen has been shown to activate PPARa and induce PPARa target genes in livers of mice (Petrick and Klaassen, 2007) .
Sample collection. At 24 h after the fourth dose of CLOF, male WT and PPARa-null mice (n ¼ 6-8/group) were anesthetized using ketamine (100 mg/kg, i.p.)/midazolam (5 mg/kg, i.p.) and the common bile duct of each mouse was cannulated with a 30-gauge needle attached to PE-10 tubing. Bile was collected from the cannula for 40 min in pre-weighed tubes on ice. The volumes of bile were determined gravimetrically, using 1.0 for specific gravity.
Another group of mice (n ¼ 6-8/group) was anesthetized with 50 mg/kg of pentobarbital at 24 h after the last dose, blood was collected from the retro-orbital sinus, and serum was obtained by centrifuging blood at 6000 Â g for 15 min. Livers, with gallbladders removed, and ileum segments were harvested from the same animals, washed, frozen in liquid nitrogen, and stored at À80 C.
BA quantification. Sample extraction and quantification of individual BAs were performed according to an ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/ MS) method described previously in Zhang and Klaassen (2010) .
Total RNA isolation. Total RNA was isolated using RNA-Bee reagent (Tel-Test Inc., Friendswood, Texas) according to the manufacturer's protocol. Total RNA concentrations were quantified spectrophotometrically at 260 nm. Integrity of RNA samples was determined by formaldehyde-agarose gel electrophoresis with visualization by ethidium bromide fluorescence under ultraviolet light.
Multiplex suspension array. The mRNAs were quantified using mutiplex suspension arrays (Panomics/Affymetrix, Fremont, California). Individual gene accession numbers can be viewed at www.panomics.com (sets No. 21330 and No. 21383) . Samples were analyzed using a Bio-Plex 200 System Array reader with Luminex 100 xMAP technology, and the data were acquired using Bio-Plex Data Manager version 5.0 (Bio-Rad, Hercules, California). Assays were performed according to the manufacturer's protocol. The mRNA data were normalized to Rpl13a mRNA and presented as relative fold change to the control group.
Statistical analysis. Data were analyzed with Student's t test. Statistical significance was set at p < .05. Bars represent mean 6 SEM (n > 5 per group).
RESULTS

CLOF Decreased BA Concentrations in Livers of WT But Not PPARa-Null Mice
Although long-term treatment with PPARa agonists (ciprofibrate and bezafibrate) have been shown to suppress BA biosynthesis in mice (Hays et al., 2005; Post et al., 2001) , the effect of shortterm PPARa activation on liver BA profile in mice remains unclear. As shown in Figure 1A , CLOF decreased the concentrations of most BAs in livers of WT mice, resulting in a 41% decrease in total BA (RBA)concentration. This decrease was not specific for a certain type of BAs, because both conjugated and unconjugated BAs, primary and secondary BAs, as well as 12a-OH and non12a-OH BAs, were all decreased or tended to be decreased. In CLOF-treated WT mice, statistically significant decreases were observed for TCDCA (39%#), Ta þ b muricholic acid (MCA) (44%#), TUDCA (54%#), CA (63%#) and bMCA (63%#). Despite decreases in individual BAs in livers of CLOF-treated WT mice, the percentages of the major BA categories were minimally changed ( Figure 1B ). In contrast, CLOF did not change either individual BAs or RBAs in livers of PPARa-null mice. To conclude, CLOF decreased the concentrations of RBAs in livers of WT mice, which is dependent on PPARa.
CLOF Slightly Increased Liver Weight and Bile Flow Relative to Body
Weight in WT Mice, But Not in PPARa-Null Mice Administration of fibrates has been shown to produce hepatomegaly and hepatic peroxisome proliferation (Gonzalez et al., 1998) . In this study, treatment with 300 mg/kg CLOF for 4 consecutive days was chosen to activate PPARa, which was confirmed by a marked increase in the mRNA expression of the PPARa target gene Cyp4a14 in livers of WT but not PPARa-null mice (Zhang et al., 2012) . As shown in Figure 2 , CLOF slightly increased liver weight (LW) per body weight (BW) (approximately 10%") in WT mice. Additionally, CLOF also produced a statistically significant increase in bile flow, whether calculated per unit LW (17%") or per unit BW (20%"). In contrast, CLOF had an opposite effect on the LW (about 15%#) in PPARanull mice. Although CLOF also increased bile flow of PPARanull mice when calculated per unit LW, this was likely due to the decrease in LW, because no change was observed in bile flow of PPARa-null mice when it was normalized to BW. Therefore, the current data suggest that PPARa activation is involved in CLOF-mediated increase in LW and bile flow in male WT mice.
CLOF Increased the Biliary Excretion of BAs in WT But Not in PPARa-Null Mice
BAs are the major determinant of bile flow. In this study, individual BA concentrations in the bile of WT and PPARa-null mice were quantified, and the biliary excretion of individual BAs was calculated per unit BW ( Figure 3A) . CLOF increased the biliary excretion of RBAs (1-fold ") in WT mice, with significant increases in total non12a-OH BAs (76%"), TCA (1.2-fold "), TaMCA (1-fold %"), TxMCA (1.3-fold "), and TUDCA (1-fold "). In contrast, alterations in the biliary excretion of BAs in PPARanull mice were resistant to CLOF treatment, except for an increase in TxMCA (59%"). BA composition is critical for cholesterol solubility in the bile and lipid absorption in the intestine.
As shown in Figure 3B , the majority of BAs in bile were conjugated primary BAs. CLOF had little effect on the percentages of major categories of BAs in bile of WT mice ( Figure 3B ). Although the total concentration of non12-hydroxylated bile acid (12-OH) BAs was increased in CLOF-treated WT mice, the percentage of non12-OH BAs tended to decrease. To summarize, PPARa activation by CLOF mediates the increased biliary excretion of BAs by CLOF treatment in WT mice, with little effect on the percentage of major BA categories in the bile. CLOF Decreased Serum BA Concentrations in WT and PPARa-Null Mice When compared with liver, only small quantities of BAs are found in the peripheral circulation. As shown in Figure 4A , CLOF decreased the concentration of RBAs in serum of WT mice (approximately 48%#), and surprisingly they were also significantly decreased in PPARa-null mice (50%#). It should be noted that the concentration of RBAs in serum was about 44% higher in WT mice than in PPARa-null mice. Significant decreases were observed for TUDCA (98%#), TDCA (83%#), TxMCA (46%#), and CA (53%#) in the serum of CLOF-treated WT mice, as well as TCA (68%#), Ta þ bMCA (66%#) ,and TxMCA (58%#) in the serum of CLOF-treated PPARa-null mice. As a result, CLOF decreased the percentages of total conjugated BAs, total primary BAs, and total CA-derived BAs (12-OH BAs) in both WT and PPARa-null mice ( Figure 4B ). To summarize, CLOF caused a suppressive effect on BA concentrations in serum of WT and PPARa-null mice.
CLOF Influenced Hepatic Expression of BA-Synthetic Enzymes and
Transporters in WT But Not in PPARa-Null Mice As shown in Figure 5 , CLOF in WT mice tended to, but not significantly, produce a 134% increase in Cyp7a1 mRNA expression. In contrast, CLOF significantly decreased Cyp7b1 (63%#). CLOF also significantly induced the BA uptake transporters (Na (þ)-taurocholate cotransporting polypeptide [Ntcp] 43%"; organic anion transporting polypeptide [Oatp]1b2 51%") and 3 efflux transporters (Mrp3 88%"; Mrp2 34%"; bile salt export pump [Bsep] 26%") in livers of WT mice. In contrast, CLOF given to PPARa-null mice had minimal effects on the hepatic expression of genes involved in BA synthesis and transport, except for a decrease in Cyp8b1 (53%#) and an increase in Oatp1b2 (39%"). Overall, CLOF showed an inductive effect on BA synthetic enzymes and transporters in livers of WT mice, and PPARa appears to be involved in CLOF-mediated regulation of BArelated genes.
CLOF Decreased the mRNA Expression of BA and Cholesterol Transporters in Ileum of WT But Not PPARa-Null Mice
The intestine is the major site for the absorption of BAs and cholesterol. As shown in Figure 6 , CLOF markedly decreased apical sodium-dependent bile acid transporter (Asbt) (37%#), Mrp2 (42%#), organic solute transporter (Ostb) (33%#), Abcg5 (39%#), and Abcg8 (43%#) in ilea of WT mice. In contrast, CLOF did not produce alterations in either BA or cholesterol transporters in the ilea of PPARa-null mice. In summary, the current data suggest a regulatory role of PPARa in CLOF-mediated decrease in BA and cholesterol transporters in the ilea of WT mice.
CLOF Decreased Genes Involved in the Intestinal Farnesoid X Receptor-Fibroblast Growth Factor15 Signaling in WT But Not PPARa-Null Mice
To evaluate the potential mechanism by which CLOF altered BA synthetic enzymes and transporters, the mRNAs of genes known to be involved in BA signaling were quantified, in particular the farnesoid X receptor (Fxr)-small heterodimer partner (Shp) signaling in the liver and the Fxr-fibroblast growth factor (Fgf)15 signaling in the intestine. Lrh-1 and Hnf4a are 2 positive regulators of Cyp7a1 in the liver. CLOF increased Lrh-1 mRNA (50%") in livers of both WT and PPARa-null mice (Figure 7) . Hnf4a was not altered in CLOF-treated WT mice, whereas it was decreased about 22% in CLOF-treated PPARa-null mice. In the ilea of WT mice, CLOF markedly decreased Fxr (37%#), Shp (73%#), Fgf15 (77%#), and Lxra (37%#). In contrast, no statistically significant change was observed in the ilea of CLOF-treated PPARa-null mice, but there was a tendency to increase Fgf15. To summarize, the current data suggest that CLOF has little effect on Fxr-Shp signaling in the liver, whereas it suppresses FxrFgf15 signaling in the ileum in a PPARa-dependent manner.
DISCUSSION
In this study, CLOF was selected because not only it has been widely used as a research tool to activate PPARa in mice, but also it shows a high selectivity to PPARa over other PPAR isoforms. Willson et al. (2000) (Fruchart, 2013) . Consequently, novel compounds with more potent and selective PPARa agonist activity have been developed in the past decade, namely selective PPARa modulators (SPPARMa). In this regard, it would be more clinically relevant to use fenofibrate or gemfibrozil or SPPARMa to elucidate the role of PPARa in BA homeostasis. Strikingly, there are no human studies with gemfibrozil in cholestasis (Ghonem et al., 2015) . Clinical trials on fenofibrate have produced controversial data on its effect in treating cholestasis. Additionally, all of them have demonstrated the potential nephrotoxic effect of fenofibrate. It is known that activation of PPARa can result in the proliferation of peroxisomes and hepatomegaly in rodents, but not in humans (Mukherjee et al., 1994) . The expression of PPARa in rodent livers is about 10 times higher than that in human livers (Palmer et al., 1998) . About 20%-50% of the total PPARa has been identified to be truncated (with exon 6 deficient) in human livers, but not in rodent livers (Lambe et al., 1999) . Not only the PPARa expression levels and isoforms, there are also species variations in PPARa target genes, which may differ in their response elements. Furthermore, a murine-specific micro-RNA let-7c signaling cascade has been attributed to be the molecular basis for the species variations of PPARa (Shah et al., 2007) . Nevertheless, as a model peroxisome proliferator and the first . Effect of CLOF on mRNA of BA and cholesterol transporters in ilea of WT and PPARa-null mice. CO or CLOF (300 mg/kg) was administered daily (i.p.) for 4 consecutive days to male WT and PPARa-null mice (n ¼ 6-8 per treatment group). QuantiGene Plex 2.0 Assay was performed to measure the gene expression of BA transporters (Asbt, Ibabp, Osta, and Ostb) and cholesterol transporters (Nieman-Picl c1-like 1 [Npc1l1], Abca1, Abcg5, and Abcg8). Relative mRNA levels were calculated with vehicle-treated WT male mice set as 100%. Data represent means 6 SEM *p < .05 versus vehicle treatment group.
FDA-approved fibrate drug, CLOF is still an important research chemical in terms of its adverse effects or potentially novel applications, such as neonatal hyperbilirubinemia (Chawla, 2017) . Therefore, these findings fill the knowledge gap on the effect of CLOF on BA homeostasis, and provide valuable evidences to interpret the potential clinical relevance.
Although altered BA metabolism has been suggested as a mechanism for its hypocholesterolemic effect, a close review of the literature reveals a surprising lack of a comprehensive analysis of the effect of CLOF on BA homeostasis. In this study, CLOF resulted in a >40% decrease in RBAs in both the liver and serum of WT mice (Figs. 2 and 4) . In contrast, PPARa-null mice demonstrated a divergent response to CLOF on BA concentrations, with RBAs in serum being decreased while RBAs in liver remained unchanged. This suggests that the regulatory function of PPARa is more prominent on BA concentrations in the liver than the serum, which is not surprising given that so many factors contribute to BA concentrations in the serum. Nevertheless, the current data suggest that CLOF decreases serum BAs in a PPARa-independent manner, whereas it decreases liver BAs through a PPARa-dependent manner.
The conventional explanation for the fibrate-mediated decrease of BA concentrations in the liver is the suppression of BA synthesis, in particular the repression of Cyp7a1, the ratelimiting enzyme of BA synthesis. This is largely based on the findings with long-term feeding of laboratory animals with fibrates. For instance, both 17 days of ciprofibrate and 12 months of bezafibrate reduced Cyp7a1 in mice (Hays et al., 2005; Post et al., 2001) . However, 2 studies revealed contradictory results on the effect of 14 days of CLOF in rats, with Cyp7a1 either unaffected or induced in liver (Hayashi et al., 1983; Stahlberg et al., 1989) . When compared with these long-term feeding studies, this study provided a more direct effect of CLOF on BA homeostasis and Cyp7a1 by taking advantage of a much shorter treatment. The present data demonstrate that CLOF tended to increase Cyp7a1 about 134% in livers of WT mice ( Figure 5) . Therefore, the decrease in liver BAs of CLOF-treated WT mice is not due to a decrease in BA synthesis. Notably, Cyp7a1 was not altered by CLOF in PPARa-null mice, indicating that PPARa is involved in increasing the expression of Cyp7a1.
Cyp7a1 expression in liver is known to be regulated by many factors, including nuclear receptors and inflammatory cytokines. Among them, the nuclear receptor Fxr is the major mechanism that regulates Cyp7a1 expression, and thus controls BA synthesis. In liver, activation of Fxr induces the expression of Shp, which in turn inhibits Lrh-1-induced transcription of Cyp7a1 (Goodwin et al., 2000) . In intestine, activation of Fxr induces Fgf15 (FGF19 in humans), which binds to the Fgfr4 receptor in liver, leading to suppression of Cyp7a1 (Inagaki et al., 2005) . In this study, CLOF had little effect on the Fxr-Shp pathway genes in liver, whereas it markedly decreased mRNAs of Fxr, Shp and Fgf15 in the ilea of WT mice (Figure 7 ). This decrease was not observed in PPARa-null mice, indicating that PPARa regulates the suppressive effect of CLOF on intestinal Fxr-Fgf15 signaling. This is consistent with a previous finding that PPARa activation decreased intestinal Fxr-Fgf15 signaling, and thus increased Cyp7a1 expression (Zhou et al., 2014) . Collectively, the increase of Cyp7a1 in CLOF-treated WT mice is not due to Fxr-Shp signaling in liver, but due to suppression of Fxr-Fgf15 signaling in intestine.
The CLOF-mediated decrease of BAs in liver was associated with an increase in bile flow and biliary excretion of BAs. CLOF increased LW and bile flow in WT mice either if bile flow was calculated per unit BW or LW. Interestingly, CLOF also increased bile flow when normalized per LW in PPARa-null mice, largely a result of reduced LWs. Nevertheless, CLOF did not alter bile flow in PPARa-null mice when bile flow was calculated per BW. Bsep and Mrp2 are 2 transporters that mediate the BA-dependent and BA-independent bile flow, respectively. CLOF induced both Bsep and Mrp2, indicating that CLOF-mediated stimulation of bile flow is both BA-dependent and BA-independent. Consistently, CLOF resulted in a 100% increase in biliary excretion of RBAs in WT mice (Figure 3 ). Biliary BA composition determines cholesterol solubility in the bile and nutrient absorption in the intestine. It is noteworthy that the ratio of CA-derived BAs (12-OHs) to CDCA-derived BAs (non12-OHs) was increased in both WT and PPARa-null mice.
So far, little is known about the regulatory role of PPARa in BA transport. The mRNAs of BA transporters in the liver, namely Ntcp, Oatp1b2, Mrp3, Mrp2, and Bsep, were increased in CLOF-treated WT mice ( Figure 5 ). In contrast, CLOF altered only Oatp1b2 in PPARa-null mice. The increase in BA uptake transporters (Ntcp and Oatp1b2) in CLOF-treated WT mice might represent an adaptive mechanism of the liver to compensate for the reduced BA concentrations in the liver. The inductive effect of PPARa activation on 3 efflux transporters in the liver (Mrp2, Mrp3, and Bsep) is consistent with our previous studies Cui et al., 2009) . CLOF also had a PPARa-dependent suppressive effect on 2 major intestinal BA transporters, namely Asbt and Ostb ( Figure 6 ). This is contradictory to the findings that Wy14643 and ciprofibrate induced ASBT mRNA expression in human intestine-derived Caco2 cells (Jung et al., 2002) . Nonetheless, reduced intestinal BA absorption may explain the decrease in serum and liver BAs in CLOFtreated mice. In addition to BA transporters, CLOF also had a PPARa-dependent suppressive effect on intestinal cholesterol transporters, with a statistically significant decrease in Abcg5/8, which are important for intestinal secretion of cholesterol. Further studies are required to investigate the effect of PPARa on protein and function of these transporters.
Previous studies on the role of PPARa in fibrate-mediated BA alterations usually involved a long-term feeding of fibrates, which may obscure the initial effect of PPARa activation on BA homeostasis. However, whether PPARa plays a regulatory role in long-term feeding of fibrates remains controversial. Ciprofibrate in the diet for 17 days reduced Cyp7a1 and Cyp27a1, and these effects were completely abolished in PPARanull mice (Post et al., 2001) . In contrast, bezafibrate in the diet for 12 months reduced BA concentrations and Cyp7a1 mRNA in livers of both WT and PPARa-null mice (Hays et al., 2005) . Thus, this study provides a systematic evaluation on the role of shortterm PPARa activation in regulating BA homeostasis. PPARa-dependent effects of CLOF on BA homeostasis are summarized in Figure 8 . In the liver, PPARa activation induces biliary transporters Mrp2 and Bsep, which leads to an increase in bile flow and the biliary excretion of BAs, resulting in a decrease in liver BA concentrations. Additionally, the target genes of PPARa in the liver also include Mrp3 and Cyp7b1, which is consistent with previous studies (Leuenberger et al., 2009) . In intestine, PPARa activation may reduce BA absorption by suppressing intestinal BA transporters (Asbt and Ostb). PPARa activation also suppresses intestinal Fxr-Fgf15 signaling, which in turn induces Cyp7a1 mRNA in the liver. Both reduced intestinal absorption of BAs and increased biliary BA secretion contribute to the decrease in liver BA concentrations, leading to a compensatory induction of liver BA uptake transporters (Ntcp and Oatp1b2).
In conclusion, this study provides a comprehensive analysis on the effect of short-term CLOF treatment on BA homeostasis in male mice. PPARa-dependent effects of CLOF include a decrease in liver BAs as well as an increase in bile flow and biliary excretion of BAs. PPARa regulates BA homeostasis through regulating gene expression in both liver and intestine. The findings in this study are critical not only in filling the knowledge gaps in our understanding for the therapeutic effects of fibrates in treating metabolic disorders, but also in elucidating the role of BAs in PPARa-mediated pharmacological and toxicological effects.
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